UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Plegridy Approval
August 18, 2014 at 07:50 AM EDT
In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Biogen Idec (NASDAQ: BIIB), but ...
